For all BMI\/sex groups, initiating colonoscopy at 45 years or annual FIT at 40 years is cost-effective at threshold of $100,000\/QALY<\/em><\/p>\n<\/h3>\n <\/b><\/p>\n <\/b><\/p>\n \n\tTHURSDAY, Aug. 11, 2022 (HealthDay News) — Initiating colonoscopy every 10 years (Colo10) at age 45 years or an annual fecal immunochemical test (FIT) at 40 years is cost-effective for all body mass index (BMI) and sex groups, according to a study published online Aug. 4 in Clinical Gastroenterology & Hepatology<\/em>.\n<\/p>\n \n\tAaron Yeoh, M.D., from the Stanford University School of Medicine in California, and colleagues compared colorectal cancer (CRC) screening starting at age 45 or 40 versus 50 years and\/or shortening screening intervals among women and men with a body mass index (BMI) ranging from normal to grade III obesity. Screening strategies included Colo10, colonoscopy every five years (Colo5), or annual FIT.\n<\/p>\n \n\tThe researchers found that sex-specific total CRC deaths were similar for persons with overweight and obesity I to III without screening, reflecting the counterbalance of increased CRC risk by lower life expectancy with increasing BMI. Colo10 starting at 45 years or FIT starting at 40 years were cost-effective at a threshold of $100,000\/quality-adjusted life-year (QALY) gained for all BMI\/sex groups. Among men with obesity II and III only, Colo10 starting at 40 years was cost-effective at $93,300 and $80,400\/QALY gained, respectively. The preference was always for shifting Colo10 to an earlier starting age rather than Colo5 starting at later ages. In a sensitivity analysis, results were robust.\n<\/p>\n \n\t“Our findings have implications for CRC screening in obese persons specifically, as well as generalizable lessons for CRC screening tailored to risk,” the authors write.\n<\/p>\n \n\tOne author disclosed financial ties to the biotechnology and medical device industries.\n<\/p>\n \n\tAbstract\/Full Text (subscription or payment may be required)<\/a>\n<\/p>\n <\/i><\/p>\n